FMC

FMC Corporation 10-Q Summary: Period Ended June 30, 2007

Business Context and Reporting Period

This Form 10-Q covers the quarterly and six-month periods ended June 30, 2007, for FMC Corporation, a diversified global chemical company. The company operates through three segments: Agricultural Products, Specialty Chemicals, and Industrial Chemicals. The financial statements are unaudited but have been reviewed by independent registered public accountants.

Key Financial Metrics

Margins: The filing does not explicitly state gross or operating margin percentages. However, segment operating profit increased 19.8% for the quarter and 13.2% for the six-month period compared to the prior year, despite significant restructuring charges.

Material Changes vs. Prior Period

• Revenue Growth: Consolidated revenue increased 11% for the quarter and 12% for the six-month period compared to 2006, driven by higher sales across all segments.
• Net Income Decline: Net income decreased significantly to $8.6 million for the quarter (from $46.3 million) and $54.4 million for the six months (from $84.0 million). This decline is primarily attributable to substantial restructuring and other charges.
• Restructuring Charges: Charges totaled $92.7 million for the quarter and $117.0 million for the six months ended June 30, 2007. Key drivers included:
  • Baltimore Phase-Out: A $75.2 million charge (including $71.0 million in asset impairments) to phase out the Agricultural Products facility in Baltimore, Maryland.
  • Solutia Settlement: A $22.5 million legal settlement regarding the Astaris joint venture.
  • Foret Facility: A $7.9 million charge for abandoning a co-generation facility.
• Discontinued Operations: Reported a loss of $5.7 million for the quarter and $15.0 million for the six months, primarily due to environmental charges and legal reserves, contrasting with income in the prior year periods.

Guidance, Outlook, and Risks

• Segment Outlook:
  • Agricultural Products: Full-year revenue growth expected in the mid-teens; operating profit expected up 30-35%.
  • Specialty Chemicals: Full-year revenue growth expected in the low-teens; operating profit expected up 20-25%.
  • Industrial Chemicals: Full-year revenue growth expected at approximately 10%; operating profit expected down approximately 5% due to higher energy costs.
• Capital Allocation: The Board authorized a new $250 million share repurchase program and increased the quarterly dividend by 17% to $0.21 per share.
• Regulatory Risks: Significant uncertainty surrounds the registration of key products (carbofuran, carbosulfan, cadusafos) in the EU and U.S. The EU Commission voted not to include these products on the approved list, requiring de-registration by December 2007. Management is litigating these decisions.
• Legal Contingencies: Ongoing antitrust litigation regarding hydrogen peroxide in the U.S. and Europe, including a pending appeal of a €25 million European Commission fine.

Investor Verification Checklist

• Baltimore Facility Impact: Verify the timeline and total cost of the Baltimore phase-out, including the estimated $50-$60 million in future charges over the next four quarters.
• EU Regulatory Status: Monitor the outcome of litigation regarding the EU de-registration of carbofuran, carbosulfan, and cadusafos, which could impact future Agricultural Products revenue.
• Environmental Reserves: Review the rollforward of environmental reserves, which increased to $178.0 million (net of recoveries), and assess the potential for additional charges at Middleport and Modesto sites.
• Antitrust Litigation: Track the status of the hydrogen peroxide antitrust cases in the U.S. and the appeal of the European Commission fine, including potential interest accruals.
• Cash Flow Sustainability: Analyze the reduction in operating cash flow ($52.6M vs $80.6M prior year) against the increased capital expenditures and debt repayment obligations.